Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?
Jacobs TW, Siziopikou KP, Prioleau JE, Raza S, Baum JK, Hayes DF, Schnitt SJ
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to compare IHC staining in CNB and SE breast cancer specimens. The time between acquisition of CNB and SE specimens ranged from 4-47 days. Slides were scored either as positive or negative for Bcl-2, ER, HER2, and p53, while factor VIII-related antigen immunostaining was used to determine MVD.
Summary of Findings
Bcl-2, ER, HER2, and p53 immunostaining results were completely concordant between all paired CNB and SE specimens (54-55 pairs). A significant correlation was observed between the MVD in CNB and SE specimens (p=0.0002), but in 42 of 49 cases, the average MVD on the CNB differed by more than 10% from the average MVD on the SE specimen. In 30 of 49 cases, MVD was higher in the CNB than the SE specimen, and in the remaining 19 cases, MVD was higher in the SE specimen. The number of 224x fields evaluated to determine MVD did not affect the percentage difference between CNB and SE specimens. Further, the authors state that no correlations were found between needle gauge or number of passes during CNB and the percentage difference in MVD between CNB and SE specimens.
Biospecimens
TissueBreastPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
ProteinImmunohistochemistryMorphologyLight microscopyPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Method of tissue acquisition Core needle biopsySurgical resectionBiospecimen Acquisition Needle gauge 13-18-gauge needle14-gauge needleBiospecimen Aliquots and Components Aliquot size/volume 1-2 224x microscope fields were evaluatedAt least 3 224x microscope fields were evaluatedBiospecimen Aliquots and Components Number of cell passages 3-6 passes5-6 passesImmunohistochemistry Specific Targeted peptide/protein Bcl-2ERFactor VIII-related antigenHER2p53